Application of a Novel Metallomics Tool to Probe the Fate of Metal-Based Anticancer Drugs in Blood Plasma: Potential, Challenges and Prospects

Although metallodrugs are used to treat a variety of human disorders and exhibit remarkable diversity therapeutic properties, they constitute only tiny minority all medicinal drugs that currently on the market. This undesirable situation must be partially attributed our general lack understanding fate in extremely ligand-rich environment bloodstream. The challenge gaining insight into these bioinorganic processes can overcome by application ‘metallomics tools’, which involve analysis biological fluids (e.g., blood plasma) with separation method conjunction multi-element specific detectors. To this end, we have developed metallomics tool is based size-exclusion chromatography (SEC) hyphenated an inductively coupled plasma atomic emission spectrometer (ICP-AES). After successful SEC-ICPAES analyze for endogenous copper, iron zinc-metalloproteins, it was subsequently applied probe metabolism metal-based anticancer plasma. versatility exemplified fact has provided individual Pt-based drugs, modulation cisplatin sulfur-containing compounds, two contain different metals as well bimetallic drug, contained metals. adding pharmacologically relevant doses plasma, temporal aliquots SEC-ICP-AES allows observe metal-protein adducts, metallodrug-derived degradation products parent metallodrug(s). unique capability obtain comprehensive extended vivo studies. Thus, novel metalcomplexes exert desired activity potential advance more animal/preclinical studies fully explore inherently offer.